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A b s t r A c t
Molecular imaging with [18F]-fluorodeoxyglucose positron emission tomography / 
computed tomography ([18F]FDG-PET/CT) has become part of the standard of care 
in oncology patients. In oncology, the quantification for the analysis of PET data is an 
important tool for tumor diagnosis, staging, determination of prognosis and assess-
ment of response to treatment. In clinical practice, standardized uptake value (SUV), 
a semi-quantitative parameter, is the most widely used parameter for the analysis of 
tracer uptake in PET imaging. The purpose of this review is to evaluate the role of 
the SUV in diagnosis, staging and restaging of the lung cancer, and also to estab-
lish the differences in [18F]FDG uptake across different histopathological subtypes 
of non-small lung cancer (NSCLC). Furthermore another purpose of the study is to 
gather and compare the SUVmax cut-off values, in differentiating benign from malig-
nant lesions, in assessing the response to treatment and finally to identify the optimal 
threshold. 
I n t r o d u c t I o n
The combination of functional metabolic and anatomical data has been available 
since 2001, when the combined positron emission tomography / computed tomography 
(PET/CT) scanner was introduced. This technology has had a significant impact on 
many medical disciplines, including cardiology and neurology but undoubtedly the 
greatest impact has been in the field of oncological imaging. In clinical practice, visual 
inspection of PET/CT images is the main tool for image interpretation and for staging 
or restaging. Ultimately, PET using [18F]fluorodeoxyglucose (FDG) was developed as 
a quantitative tool and its quantitative characteristics are increasingly being recognized 
as providing an objective, more accurate, and less observer-dependent measure for 
prognosis and response monitoring purposes than visual inspection alone. The most 
commonly used measure of [18F]FDG uptake is the standard uptake value (SUV). 
Other synonymous terms for SUV, in the literature, are DUR (dose uptake ratio) 
or SUR (standard uptake ratio).1 The definition of SUV is tissue uptake (μCi/mL) 
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divided by whole body administered activity, normalized for 
body weight (mCi/Kg).1
SUV = tissue uptake (μCi/mL) /  
administered activity (mCi/Kg)
The standardized uptake value although it is regarded as 
unitless, it has the dimensions of density (g/mL) but most of the 
body has density close to 1.0, so the units are usually ignored.2 
Although SUV is a simple, straight forward concept, there are 
significant problems with it. Table 1 lists the most important 
sources of error concerning SUV, which we have to avoid.2
L u n g  c A n c e r  d I A g n o s I s
Lung cancer imaging using PET with the glucose analogue 
[18F]FDG is based on the enhanced glucose metabolism of 
cancer cells. [18F]FDG undergoes the same uptake as glucose 
but is metabolically trapped and accumulated in the cytoplasm 
of cancer cells after phosphorylation by hexokinase. The pat-
tern of [18F]FDG distribution in the body detected on PET/CT 
allows differentiation between normal and malignant tissues. 
In questionable cases of pulmonary nodules, the prolonged 
observation of the metabolic activity and the SUV value in 
delayed imaging, meaning at 90 minutes post injection or more, 
has been proven to aid in the differential diagnosis. Hilar or 
mediastinal lymph nodes with [18F]FDG uptake higher than 
the surrounding tissue, as determined by qualitative analysis 
and SUVmax value more than 2 (as determined by quantitative 
analysis), were considered positive findings. Also, the assess-
ment of the SUVmax in PET/CT findings has the potential to 
differentiate an adenocarcinoma in situ and minimally invasive 
adenocarcinoma from invasive adenocarcinomas. A study from 
2009, when the term bronchioloalveolar carcinoma (BAC) 
was still used, showed that the SUVmax can differentiate the 
adenocarcinoma with BAC from other subtypes of non-small 
cell lung cancer (NSCLC).3 A nodule with a mixed pattern 
with partly solid and ground glass opacity was significantly 
more frequent CT feature of an adenocarcinoma with BAC 
(50%) compared to the other subtypes (1.8%) (p<0.0001).3 
Maximum SUV of adenocarcinoma with BAC was significantly 
lower than that of other subtypes of NSCLC (p<0.0001). 
Sensitivity, specificity, positive predictive value, and negative 
predictive value of CT for differentiating adenocarcinoma 
with BAC from other subtypes was 50%, 98.2%, 80%, and 
93%, respectively.3 Sensitivity, specificity, positive predictive 
value, and negative predictive value of combination of two 
modalities, [18F]FDG-PET and CT, was 81.3%, 85.3%, 44.8%, 
and 96.9,%, respectively.3 Furthermore, in surgically managed 
lung cancer patients, SUVmax is a predictor of overall survival 
after resection. The addition of SUVmax to pathologic tumor 
size identifies a subgroup of patients at high risk for death as 
a result of recurrent disease after resection.4 
s t A g I n g
The tumor-node-metastasis (TNM) staging system is 
considered the most important tool to estimate prognosis and 
to date is the most important guide in treatment decisions. 
However, the TNM staging system provides an incomplete 
biologic profile of NSCLC, thus, it is far from perfect as a 
prognostic indicator. Quantitative measures of biologic ag-
gressiveness, like [18F]FDG uptake, could be better indicators 
tAbLe 1. The most important sources of error in the SUV measurement 
biological Factor effect
Blood glucose level
Uptake period
Patient motion/breathing
Patient comfort
Inflammation
Increased blood glucose level = lower SUV value 
Increased time interval between injection and start of PET study= higher SUV
Imaging artefacts in case of mismatch in position between CT and PET scan and 
resolution loss due to respiratory motion (possible lower SUV)
Patient stress and uncomfortable waiting conditions increase uptake of FDG in 
muscle and/or brown fat and may effect SUV quantification
Inflammatory processes near or at the tumor site may result in a false positive 
increase of SUV
error effect
Incorrect synchronization of clocks of PET camera 
and dose dispensing system
Use of injection time rather than dose dispensing 
time (or use of incorrect amount of dose)
Incorrect decay correction resulting in incorrect SUV
Incorrect time interval used for decay correction of the administered dose 
results in incorrect SUV.
CT = computed tomography; FDG = fluorodeoxyglucose; PET = positron emission tomography; SUV = standardized uptake value
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for survival and risk of recurrence, and thus for selection of 
patients for adjuvant treatment. For prognostic stratification, 
the SUVmax can be calculated using a single whole-body [18F]
FDG-PET scan that is routinely performed in patients with 
NSCLC as part of their pre-therapeutic staging procedure 
in most of the countries worldwide, as well as in Greece. A 
great advantage of measurement of [18F]FDG uptake is that 
this can be done before any treatment has been performed. 
The prognostic value of [18F]FDG-PET at diagnosis has been 
evaluated in several studies. These studies have shown that the 
pre-therapeutic [18F]FDG-PET not only improved patient stag-
ing, but also provided prognostic information (Table 2).5-15 All 
studies showed that patients with low [18F]FDG uptake values 
in their primary tumor have a significant longer overall- and 
progression-free survival than patients with high [18F]FDG 
uptake. Higashi et al16 and Sasaki et al17 found that [18F]FDG 
uptake in the primary tumor was a better prognostic variable 
than pathologic TNM system staging in predicting recurrence 
of patients with NSCLC. Sasaki et al observed that patients 
with high SUVs of their regional lymph nodes and low SUVs 
in their primary tumors did not experience any local or distant 
recurrence.17 Therefore, it is at least speculated that the SUVs 
for the regional lymph nodes do not agree with and are not 
stronger prognostic factors than the SUVs for the primary 
tumor.
In previously published studies, univariate analyses have 
been performed to determine a cut-off point for the SUV in 
the primary tumor to discriminate between a more or less 
favorable prognosis. It has been assessed that the cut-off of 
SUV value ranges widely from 5 to 20. Sasaki et al and Hisaghi 
et al reported that the patient group with SUV cutoff value 
of 5 had better prognosis.16-17 On the other edge, Dhital et al 
have proposed a significantly higher SUV cutoff value of 20.18 
Jeong et al,19 as well as Vansteenkiste et al,20 found a cut-off of 
7, Downey et al21 a cutoff of 9, and Ahuja et al22 a cutoff of ≈10.
r e s t A g I n g  A n d  r e s p o n s e  
t o  t r e A t m e n t
The conventional approach to determine if a tumor is 
responding to chemotherapy or radiotherapy is the size 
measurement using computed tomography (CT) or magnetic 
resonance imaging (MRI) and see if the tumor is being de-
creased or increased in size over time. It has been proven that 
the metabolic changes precede changes in the tumor size.23 
Quantitative measures of FDG uptake have started to be used 
as a way to access response to therapy.24-25 It is likely that SUV 
will become an important measure of response to therapy 
that will be combined with other parameters such as circulat-
ing tumor markers and size measured with CT or MRI. The 
major questions in using [18F]FDG-PET to assess response to 
therapy are when to image and what decrease of SUV value 
is considered indicative of response. General guidelines are 
to wait 3-4 weeks after chemotherapy, 1 month after surgery 
and 3-4 months after radiotherapy.26
Several studies have indicated a possible role for PET 
in assessment of response during or after radiotherapy25, or 
induction chemotherapy,26-27 or a combination thereof.28-32 In 
one of these studies, patients with a higher [18F]FDG uptake 
on their baseline PET showed a better response to treatment. 
The recurrence rate was higher in lesions that revealed higher 
[18F]FDG uptake at baseline, as well as after treatment. Also a 
more prominent decrease in the [18F]FDG uptake was noted 
in patients with a response on CT measurement, compared 
with those with no change on CT. In the pilot study of Van-
steenkiste et al,27 who studied 15 patients before and after 
induction chemotherapy, a reduction in [18F]FDG uptake 
of at least 50% in the primary tumor or mediastinal clear-
ance proved to be a better predictor of long-term survival 
compared with the standard WHO criteria used for response 
assessment on CT. 33-34 Another study that evaluated response 
monitoring of induction chemotherapy showed that [18F]
FDG-PET identified prognostically different strata in patients 
considered responsive according to CT.26 In this prospective 
multicenter study, [18F]FDG-PET was performed before, 
after 1 and 3 cycles of induction chemotherapy. 26 This was 
the only study that evaluated [18F]FDG-PET at an earlier 
and perhaps clinically more relevant stage of treatment. The 
accuracy of a dynamic [18F]FDG-PET scan in the predic-
tion of pathological tumor response was 83% to 96%.26 The 
SUVmax in the mediastinal lymph nodes after completion of 
radio-chemotherapy predicted the histopathologic lymph node 
status after radio-chemotherapy with a sensitivity and specific-
ity of 73% and 89%.35 Significantly more patients with a larger 
percentage decrease in SUVmax in the primary tumor during 
induction therapy stayed free from extra cerebral recurrence 
compared with patients with a lesser response (83% vs 46% 
at 16 months). 35 All studies showed that [18F]FDG-PET is a 
significant predictor of therapy outcome and provides results 
of great prognostic significance.
c o n c L u s I o n
Quantitation of [18F]FDG uptake using SUVmax is a 
simple and robust measure of the degree of uptake and thus 
the metabolic rate of a tumor. It is useful for assessing the 
probability that a mass is malignant or that a known tumor 
is responding to therapy. The key role of SUVmax in many 
parameters of [18F]FDG-PET imaging allows us to have the 
ability to face the challenges not only in diagnosis but also in 
staging and restaging. It is a valuable tool that should be used 
on a regular basis to assist in the interpretation of [18F] FDG 
PET studies. 
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tAbLe 2. Studies evaluating the prognostic  formation of [18F]FDG uptake (SUVmax value) in patients with NSCLC 
reference n of patients Histology of carcinoma stage treatment survival p value
 5 155 Squamous 37%
Adenocarcinoma 34%
Large-cell 7%
Undetermined 22%
I or II 45%
III 35%
IV 20%
Unspecified Median survival (months)
SUV >10 11.4
SUV ≤10 24.6
0.0049
 6 125 Squamous 54%
Adenocarcinoma 25%
Large-cell 21%
I 37%
II 15%
IIIA 30%
IIIB 18%
Resection 73%
Nonsurgical 27%
2-y survival
SUV >7 43%
SUV ≤7 83%
0.001
 7 38 Squamous 32%
Adenocarcinoma 50%
Large-cell 18%
I 19%
II 13%
IIIA 50%
IIIB 3%
IV 13%
Resection 76%
Nonsurgical 24%
3-y survival
SUV >8.72 40%
SUV ≤8.72 70%
0.2256
 8 77 Squamous 58%
Adenocarcinoma 23%
Large-cell 13%
Other 5%
All stages
≤IIIA
Not reported Median survival
SUV >20 6
SUV ≤20 33
0.001
 9 57 Squamous 14%
Adenocarcinoma 23%
Large-cell 2%
BAC 23%
Adenosquamous 2%
I 81%
IA 67%
IB 14%
II 2%
III 17%
Resection 100% 5-y survival
SUV >5 20%
SUV ≤5 90%
5-y free survival
SUV >5 17% 
SUV ≤5 88%
0.0002
<0.0001
 10 73 Squamous 51%
Adenocarcinoma 41%
Large-cell 3%
BAC 5%
I 44%
II 23%
IIIA 7%
IIIB 19%
IV 7%
Resection 92%
Nonsurgical 8%
2-y survival
SUV ≥7 56%
SUV <7 96%
0.0011
 11 100 Squamous 24%
Adenocarcinoma 67%
Large-cell 3%
Adenosquamous 2%
Carcinoid 4% 
All T1-4,N0-2
M0
R0 resection 100% 2-y survival
SUV >9 68%
SUV <9 96%
<0.01
 12 162 Squamous 43%
Adeno or large-cell 46%
Other 10%
I 40%
II 16%
IIIA 20%
IIIB 24%
Resection 57%
Radical radio 43%
2-y survival
SUV >5 65%
SUV ≤5 94%
0.02
 13 315 Squamous 54%
Adenocarcinoma 33%
Other 13%
IA 19%
IB 26%
II 18%
IIIA 23%
IIIB 5%
IV 9%
Resection 71%
Nonsurgical 29%
Mean survival
SUV ≥10 1.6
SUV <10 3.2
<0.0001
 14 51 Squamous 33%
Adenocarcinoma 25%
Large-cell 20%
Other 22%
I 41%
II 22%
III 37%
Radical radio 100% 2-y survival
SUV ≥15 27%
SUV <15 60%
<0.0001
 15 137 Squamous 45%
Adenocarcinoma 29%
Large-cell 12%
Other 14%
IIIA 43%
IIIB 57%
Chemoradiation
100%
Median survival
SUV >12 9
SUV <12 22
0.05
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